Exclusive image guided IMRT vs. radical prostatectomy followed by postoperative IMRT for localized prostate cancer: a matched-pair analysis based on risk-groups

Table 3 Three and 5-year FFF rates from the start of any treatment with comparison of patient-, tumor- and treatment-related characteristics (univariate analysis)

Characteristics	Events (n)/patients (n)	3-year FFF rates - % [range]	5-year FFF rates - % [range]	Log-rank test
Characteristics	Events (n)/patients (n)	3-year FFF rates - % [range]	5-year FFF rates - % [range]	p-value
Treatment				0.0311*
IG-IMRT	3/49	95.87% [84.49%-98.95%]	93.14% [79.96%-97.76%]
RP + IMRT	9/49	87.61% [74.48%-94.24%]	76.46% [58.31%-87.50%]
Age
≤ 66.8 years	5/49	91.74% [79.47%-96.82%]	88.35% [73.58%-95.12%]	0.595
> 66.8 years	7/49	91.59% [79.08%-96.76%]	83.00% [67.17%-91.65%]	0.595
Tumor stage
T1	8/60	91.44% [80.61%-96.35%]	84.37% [70.75%-91.99%]	0.758
T2	4/38	92.11% [77.49%-97.38%]	87.72% [69.57%-95.38%]	0.758
Gleason score
≤ 6	5/58	96.52% [86.80%-99.12%]	89.15% [75.57%-95.40%]	0.135
7	7/40	84.68% [68.98%-92.82%]	81.29% [64.45%-90.69%]	0.135
Pretherapeutic PSA
≤ 8.7 ng/mL	4/49	93.83% [82.08%-97.97%]	90.99% [77.46%-96.57%]	0.250
> 8.7 ng/mL	8/49	89.55% [76.67%-95.52%]	80.69% [64.58%-90.01%]	0.250
Concomitant ADT
No	12/78	89.53% [80.13%-94.63%]	82.02% [70.12%-89.52%]	0.070
Yes	0/20	100 [ND – ND]	100 [ND – ND]	0.070
Adjuvant ADT
No	12/84	90.29% [81.51%-95.03%]	83.44% [72.36%-90.36%]	0.156
Yes	0/14	100 [ND – ND]	100 [ND – ND]

FFF: Freedom from biochemical failure; ADT: androgen deprivation therapy; * the definition of biochemical failure in the RP + IMRT group is a PSA threshold of ≥ 0.1 ng/mL.

ISSN: 1748-717X